RecruitingNCT06800612

Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

100 participants

Start Date

Mar 22, 2024

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Metastatic Ovarian Cancer Endometrial Cancer Cervical Carcinoma Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Summary

retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a data collection study looking at how well different cancer drug therapies work for women with breast cancer or gynecologic cancers (such as ovarian, cervical, or uterine cancer) — including both early-stage and metastatic disease. **You may be eligible if...** - You have a confirmed diagnosis of breast cancer or a gynecologic cancer - You have received treatment for this cancer since January 2010 - You are currently alive and able to give consent to participate **You may NOT be eligible if...** - There are no specific exclusion criteria for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOncologic drugs administered for treatment of breast cancer

Data on oncologic drugs administered for treatment of breast cancer will be recorded

DRUGOncologic drug administered for treatment of gynecologic cancer

Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded

Locations(1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06800612

Related Trials

DESTINY-PANTUMOUR04

NCT0712400017 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT0731855828 locations

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

NCT067605071 location

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467164 locations